Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery

Powder Technology

Volumn 236, Issue , 2013, Pages 132-138

  Ober, Courtney A ^a   Kalombo, Lonji ^b   Swai, Hulda ^b   Gupta, Ram B ^a  

^a AUBURN UNIVERSITY   (United States)

^b DSI CSIR Nanotechnology Innovation Centre   (South Africa)

Author keywords

Dry powder inhaler; Lactose; Micronization; Rifampicin; SAS DEM; Supercritical antisolvent

Indexed keywords

DRY POWDER INHALER; LACTOSE; MICRONIZATIONS; RIFAMPICIN; SAS-DEM; SUPERCRITICAL ANTISOLVENTS;

CARBON DIOXIDE; DIFFERENTIAL SCANNING CALORIMETRY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; LIQUIDS; METHANOL; MIXING; ORGANIC SOLVENTS; SCANNING ELECTRON MICROSCOPY; SOLVENTS; X RAY DIFFRACTION;

SUGARS;

CARBON DIOXIDE; EXCIPIENT; LACTOSE; METHANOL; RIFAMPICIN; SOLVENT;

ARTICLE; CHEMICAL INTERACTION; CHEMICAL PROCEDURES; CONCENTRATION (PARAMETERS); CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; HEATING; HYPERBARISM; INFRARED SPECTROSCOPY; INHALATIONAL DRUG ADMINISTRATION; LIQUID; LUNG TUBERCULOSIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; SCANNING ELECTRON MICROSCOPY; SOLVENT EXTRACTION; SUPERCRITICAL ANTISOLVENT DRUG EXCIPIENT MIXING TECHNIQUE; SUPERCRITICAL FLUID; SUSPENSION; X RAY DIFFRACTION;

EID: 84873739654     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2012.04.057     Document Type: Article

References (29)

1. WHO Tuberculosis Fact Sheet 2010, World Health Organization, Geneva. WHO
2. Schreiber J., Zissel G., Greinert U., Schlaak M., Müller-Quernheim J. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. European Journal of Medical Research 1999, 4:67.
3. Groneberg D.A., Witt C., Wagner U., Chung K.F., Fischer A. Fundamentals of pulmonary drug delivery. Respiratory Medicine 2003, 97:382-387.
4. Prime D., Atkins P.J., Slater A., Sumby B. Review of dry powder inhalers. Advanced Drug Delivery Reviews 1997, 26:51-58.
5. Swai H., Semete B., Kalombo L., Chelule P., Kisich K., Sievers B. Nanomedicine for respiratory diseases. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology 2009, 1:255-263.
6. Gupta R.B., Kompella U.B. Nanoparticle technology for drug delivery 2006, Informa Health Care.
7. Heyder J., Rudolf G. Mathematical models of particle deposition in the human respiratory tract. Journal of Aerosol Science 1984, 15:697-707.
8. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 [mu] m. Journal of Aerosol Science 1986, 17:811-825.
9. Rifampin Tuberculosis 2008, 88:151-154. Rifampin
10. Becker C., Dressman J.B., Junginger H.E., Kopp S., Midha K.K., Shah V.P., et al. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. Journal of Pharmaceutical Sciences 2009, 98:2252-2267.
11. Changsan N., Chan H.K., Separovic F., Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. Journal of Pharmaceutical Sciences 2009, 98:628-639.
12. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrobial Agents and Chemotherapy 2007, 51:3781.
13. Reverchon E., De Marco I., Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation. International Journal of Pharmaceutics 2002, 243:83-91.
14. Sung J.C., Padilla D.J., Garcia-Contreras L., VerBerkmoes J.L., Durbin D., Peloquin C.A., et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharmaceutical Research 2009, 26:1847-1855.
15. O'Hara P., Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharmaceutical Research 2000, 17:955-961.
16. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharmaceutical Research 2001, 18:1315-1319.
17. Patomchaiviwat V., Paeratakul O., Kulvanich P. Formation of inhalable rifampicin-poly (l-lactide) microparticles by supercritical anti-solvent process. AAPS PharmSciTech 2008, 9:1119-1129.
18. Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. European Journal of Pharmaceutical Sciences 2007, 32:140-150.
19. Mizoe T., Ozeki T., Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 2008, 9:755-761.
20. Darbandi M.A., Rouh A.N.A., Gilani K., Tajerzadeh H. The effect of vehicles on spray drying of rifampicin inhalable microparticles: in vitro and in vivo evaluation. Daru 2008, 16:128-135.
21. Tewes F., Brillault J., Couet W., Olivier J.C. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. Journal of Controlled Release 2008, 129:93-99.
22. Son Y.J., McConville J.T. A new respirable form of rifampicin. European Journal of Pharmaceutics and Biopharmaceutics 2011, 78:366-376.
23. Sanganwar G.P., Sathigari S., Babu R.J., Gupta R.B. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. European Journal of Pharmaceutical Sciences 2010, 39:164-174.
24. Sathigari S.K., Ober C.A., Sanganwar G.P., Gupta R.B., Babu R.J. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement. Journal of Pharmaceutical Sciences 2011, 100:2952-2965.
25. FDA Inactive Ingredient Search for Approved Drug Products 2011, U.S. Department of Health and Human Services, Washington, D.C. FDA
26. Pelizza G., Nebuloni M., Ferrari P., Gallo G.G. Polymorphism of rifampicin. Il Farmaco; Edizione Scientifica 1977, 32:471.
27. Henwood S.Q., Liebenberg W., Tiedt L.R., Lotter A.P., de Villiers M.M. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Development and Industrial Pharmacy 2001, 27:1017-1030.
28. Rohrs B.R., Amidon G.E., Meury R.H., Secreast P.J., King H.M., Skoug C.J. Particle size limits to meet USP content uniformity criteria for tablets and capsules. Journal of Pharmaceutical Sciences 2006, 95:1049-1059.
29. Agrawal S., Ashokraj Y., Bharatam P.V., Pillai O., Panchagnula R. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. European Journal of Pharmaceutical Sciences 2004, 22:127-144.